TABLE 2

Summary of rat in vivo pharmacokinetic properties of SEN12333

The table summarizes results obtained from independent studies. A, to determine oral bioavailability of SEN12333, Wistar rats were injected either with 5 mg/kg i.v. or 10 mg/kg p.o., and plasma concentrations of SEN12333 were determined at 10 time intervals up to 24 h (n = 3). B, to determine brain-to-plasma ratio, rats were injected with SEN12333 10 mg/kg i.p., and individual plasma and brain concentrations of SEN12333 were determined after 0.5, 1, and 3 h (n = 3).

Matrix
Administration Route
Dose
Tmax
t½
Cmax
AUC
Clp
Vss
Brain-Plasma Ratio
F
mg/kg h h Ng/ml h · ng/ml ml/min/kg l/kg %
A Plasma i.v. 5 0.8 2058 2013 43 2.5
Plasma p.o. 10 0.67 1.5 853 2293 57
B Plasma i.p. 10 0.5 0.8 244 347
Brain
i.p.
10
0.5
1
644
809
2.5

  • Clp, plasma clearance; F, bioavailability; Vss, volume of distribution at steady state.